I am teaming up with the great staff of http://www.drunktrader.com/ in search of some missing IT ware. Both DT and me plus our staff have co-operated in the past on several ventures and to hear that Isis has pulled this type of behavior is unacceptable. We will be joining forces both online and in person to see this injustice is dealt with.
It's quite possible that the entire team of BT101 will be summoned to a fact finding mission to Chicago in the coming days. Please understand that while clinical trial data and biotech stocks are our top priority, one must always step up when a friend is in need. I will keep you updated.
Thursday, July 31, 2008
Monday, July 28, 2008
Amgen Still Rolling on results
Amgen Inc. led drug stocks higher early Monday, as the biotech giant gained on a report of progress with an osteoporosis drug candidate, denosumab.
Late Friday, Amgen released favorable data for denosumab, a product many investors are hoping can jump-start the biotech group's top line. Amgen's financial performance has been lackluster this year, due largely to weakened sales for its flagship anemia drugs Aranesp and Epogen amid heightened safety concerns.
Late Friday, Amgen released favorable data for denosumab, a product many investors are hoping can jump-start the biotech group's top line. Amgen's financial performance has been lackluster this year, due largely to weakened sales for its flagship anemia drugs Aranesp and Epogen amid heightened safety concerns.
Amgen is slated to release its second-quarter earnings report after the market closes on Monday.
I'll get some info on denosumab (another monoclonal antibody therapy) and get another post up with an explanation. Stay tuned.
AMGN is trading at 60.58, +6.67, +12.4% in afternoon action.
Tuesday, July 22, 2008
BioTech Market Update:
The staff at Bio took the day off today and hit up Where the Surf Meets the Turf at Del Mar. The racing was good, the betting better and the scenery the best. Nothing like hanging out by the Pacific, beautiful women and men and the best jockeys the sport has to offer. Did I mention they have beer?
Here's what happened whilst 101 staff was gambling away their salaries:
Biotech stocks got a nice boost early Monday from news that Swiss drugmaker Roche plans to buy the remaining 44% of Genentech Inc. that it doesn't already own for $43.7 billion.
The Amex Pharmaceutical Index was down marginally at 306.0 while the Amex Biotechnology Index, of which Genentech is a component, jumped 3% to 819.5.
Genentech shares soared 14% to $93.52, notably above Roche's bid price of $89 a share, indicating investors may be anticipating a counter-offer.
Early Monday, Roche announced its bid, stating the merger would stream-line drug discovery and increase productivity. The deal would also give Roche total control over Genentech's marketed products, which include such oncology drugs as Avastin, Herceptin and Rituxan.
Genentech is a leading marketer of biologic oncology drugs. Roche sells Genentech's products overseas, while the biotech group markets them in the U.S.
Shares of partners Merck & Co. and Schering-Plough Corp. fell on news that they were delaying release of their respective quarterly financial reports, which were expected early Monday morning, until after market close.
The companies attributed the postponement to the expected release of new data on their controversial cholesterol drug Vytorin at 1:00 p.m. ET.
Sales of Vytorin have been in the dumps since this winter, when a medical study showed the drug wasn't any more effective in battling heart disease than generic versions of Merck's cholesterol drug Zocor. Vytorin is a combination of Zocor, which lost patent protection in 2006, and a newer drug called Zetia.
Biogen Idec shares were up 5% at $67.95. The biotech, which is slated to roll out its earnings report early Tuesday, co-markets Genentech's blockbuster oncology drug Rituxan.
Also climbing was Biogen partner Elan Corp. Elan and Biogen market the multiple sclerosis therapy Tysabri.
Here's what happened whilst 101 staff was gambling away their salaries:
Biotech stocks got a nice boost early Monday from news that Swiss drugmaker Roche plans to buy the remaining 44% of Genentech Inc. that it doesn't already own for $43.7 billion.
The Amex Pharmaceutical Index was down marginally at 306.0 while the Amex Biotechnology Index, of which Genentech is a component, jumped 3% to 819.5.
Genentech shares soared 14% to $93.52, notably above Roche's bid price of $89 a share, indicating investors may be anticipating a counter-offer.
Early Monday, Roche announced its bid, stating the merger would stream-line drug discovery and increase productivity. The deal would also give Roche total control over Genentech's marketed products, which include such oncology drugs as Avastin, Herceptin and Rituxan.
Genentech is a leading marketer of biologic oncology drugs. Roche sells Genentech's products overseas, while the biotech group markets them in the U.S.
Shares of partners Merck & Co. and Schering-Plough Corp. fell on news that they were delaying release of their respective quarterly financial reports, which were expected early Monday morning, until after market close.
The companies attributed the postponement to the expected release of new data on their controversial cholesterol drug Vytorin at 1:00 p.m. ET.
Sales of Vytorin have been in the dumps since this winter, when a medical study showed the drug wasn't any more effective in battling heart disease than generic versions of Merck's cholesterol drug Zocor. Vytorin is a combination of Zocor, which lost patent protection in 2006, and a newer drug called Zetia.
Biogen Idec shares were up 5% at $67.95. The biotech, which is slated to roll out its earnings report early Tuesday, co-markets Genentech's blockbuster oncology drug Rituxan.
Also climbing was Biogen partner Elan Corp. Elan and Biogen market the multiple sclerosis therapy Tysabri.
Saturday, July 19, 2008
Off topic...But well worth it
GOOG once again was in left field concerning it's 2Q earnings report. Check this youtube video:
http://www.youtube.com/watch?v=mJXxmiKv3hw
http://www.youtube.com/watch?v=mJXxmiKv3hw
Friday, July 18, 2008
PPHM---Peregrine Pharma
I'm looking at them carefully. I can post some of their "promising" pipeline drugs, if there are any at 37 cents a share.
Might have to pick up some shares and anticipate a bump up the closer fall comes. Stay tuned.
Might have to pick up some shares and anticipate a bump up the closer fall comes. Stay tuned.
Sunday, July 13, 2008
The Market is down: There is still action to be had in BioTech
Check out what happened in biotech on friday just before market close. ANDS had a nice spike right before the market closed jumping up 66 cents a share to close at $2.97. This should be a reaction to the news that they are returning to Hep C treatment with their drug termed ANA598:
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for cancer. The company was founded in 1992. It was formerly known as ScripTech Pharmaceuticals, Inc. and changed its name to Scriptgen Pharmaceuticals, Inc. in 1994. Later, the company changed its name to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for cancer. The company was founded in 1992. It was formerly known as ScripTech Pharmaceuticals, Inc. and changed its name to Scriptgen Pharmaceuticals, Inc. in 1994. Later, the company changed its name to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California.
Thursday, July 03, 2008
Illumina hits record high....Nice time to be in their ESPP
Illumina shares reach record high as analysts reaffirm positive sales outlook
NEW YORK (AP) -- Shares of genetic analysis instrument maker Illumina Inc. reached an all-time high Wednesday as analysts reaffirmed a positive sales outlook for the company.
Shares reached $91.41 during the trading session, before retreating. The stock maintained a gain of $1.55, or 1.8 percent, to close at $90.10.
Goldman Sachs analyst May-Kin Ho raised her second-quarter profit forecast for the company to 30 cents from 29 cents per share and counted Illumina among biotech companies that will excel because of sales. For the year, she expects profit of $1.23 per share, up from prior forecasts for $1.19 per share.
The company, meanwhile, expects second-quarter profit of 37 to 40 cents per share, topping the 28 cents per share expected by analysts surveyed by Thomson Financial.
During the first quarter, Illumina swung to a profit as analytic instrument sales more than doubled with the help of its Genome Analyzer and Genome Analyzer II systems.
Ho previously said the company's profit could increase by about 32 percent per year over the next few years. She and others view the company's Genome Analyzer II system as a key player in pushing the company's profit.
More tomorrow and just what this Analyzer thing is. check back.
NEW YORK (AP) -- Shares of genetic analysis instrument maker Illumina Inc. reached an all-time high Wednesday as analysts reaffirmed a positive sales outlook for the company.
Shares reached $91.41 during the trading session, before retreating. The stock maintained a gain of $1.55, or 1.8 percent, to close at $90.10.
Goldman Sachs analyst May-Kin Ho raised her second-quarter profit forecast for the company to 30 cents from 29 cents per share and counted Illumina among biotech companies that will excel because of sales. For the year, she expects profit of $1.23 per share, up from prior forecasts for $1.19 per share.
The company, meanwhile, expects second-quarter profit of 37 to 40 cents per share, topping the 28 cents per share expected by analysts surveyed by Thomson Financial.
During the first quarter, Illumina swung to a profit as analytic instrument sales more than doubled with the help of its Genome Analyzer and Genome Analyzer II systems.
Ho previously said the company's profit could increase by about 32 percent per year over the next few years. She and others view the company's Genome Analyzer II system as a key player in pushing the company's profit.
More tomorrow and just what this Analyzer thing is. check back.
Tuesday, July 01, 2008
Biotech Market update: 1 July 2008
BioTech/Big Pharma stocks in the news, 10am PST.
Drug stocks slipped in early action Tuesday, but shares of Myriad Genetics rebounded from a sell-off in the previous session over its move to discontinue development of its Alzheimer's disease drug candidate Flurizan.
Myriad shares were up 4% at $47.30.
Myriad reported disappointing Phase III clinical results for Flurizan early Monday, an event that had been widely predicted by industry watchers on Wall Street. The company had been developing the compound for the treatment of mild cases of Alzheimer's disease.
Drug stocks slipped in early action Tuesday, but shares of Myriad Genetics rebounded from a sell-off in the previous session over its move to discontinue development of its Alzheimer's disease drug candidate Flurizan.
Myriad shares were up 4% at $47.30.
Myriad reported disappointing Phase III clinical results for Flurizan early Monday, an event that had been widely predicted by industry watchers on Wall Street. The company had been developing the compound for the treatment of mild cases of Alzheimer's disease.
Myriad's bad news appeared to ripple over into shares of other drugmakers working on Alzheimer's medications.
Subscribe to:
Posts (Atom)
